{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:03:30Z","timestamp":1768453410681,"version":"3.49.0"},"reference-count":64,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,10,30]],"date-time":"2006-10-30T00:00:00Z","timestamp":1162166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2007,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A gene splicing technique was used to create a hybrid fusion protein DTAT encoding the 390 amino acid portion of diphtheria toxin (DT<jats:sub>390<\/jats:sub>), a linker, and the downstream 135\u2010amino terminal fragment portion of human urokinase plasminogen activator. DTAT was assembled to target human glioblastoma cell lines in a murine intracranial model. Previously published <jats:italic>in vitro<\/jats:italic> studies demonstrated that DTAT was highly selective and toxic to human glioblastoma cell lines in a flank tumor model. The purpose of this study was to determine the toxicity, specificity and possible therapeutic efficacy of DTAT in an intracranial model. Convection enhanced delivery of DTAT resulted in about a 16\u2010fold increase in maximum tolerated dose. Intracranial administration of DTAT on an every\u2010other\u2010day basis in nude mice with established U87 MG brain tumors resulted in significant reductions in tumor volume and significantly prolonged survival (<jats:italic>p<\/jats:italic> &lt; 0.0001). Magnetic resonance imaging proved to be a powerful tool in mice and rats for demonstrating tumor growth in a xenograft intracranial model, assessing the efficacy of DTAT in tumor volume reduction and detecting DTAT\u2010associated intracranial toxicity and vascular damage. These results suggest that the DTAT recombinant fusion protein is highly effective in an intracranial model and DTAT might be an effective treatment for glioblastoma. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.22278","type":"journal-article","created":{"date-parts":[[2006,10,30]],"date-time":"2006-10-30T20:41:07Z","timestamp":1162240867000},"page":"411-419","source":"Crossref","is-referenced-by-count":20,"title":["Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice"],"prefix":"10.1002","volume":"120","author":[{"given":"Edward","family":"Rustamzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"Todhunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent D.","family":"Vallera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter C.","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Panoskaltsis\u2010Mortari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Vallera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,10,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02700025"},{"key":"e_1_2_6_3_2","first-page":"5016","article-title":"Expression and localization of urokinase\u2010type plasminogen activator receptor in a human gliomas","volume":"54","author":"Yamamoto M","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006339717748"},{"key":"e_1_2_6_5_2","first-page":"1079","article-title":"Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer","volume":"1","author":"Grondahl\u2010Hansen J","year":"1995","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00170-N"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2214"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.blo0000093845.72468.bd"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb08132.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1016\/S0021-9258(19)39348-2","article-title":"The human receptor for urokinase plasminogen activator. NH2\u2010terminal amino acid sequence and glycosylation variants","volume":"265","author":"Behrendt N","year":"1990","journal-title":"J Biol Chem"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)66635-9"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)98963-5"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)81042-7"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.8.597"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-200010000-00050"},{"key":"e_1_2_6_16_2","first-page":"5218","article-title":"Immuntoxin and vascular leak syndrome","volume":"6","author":"Vitetta ES","year":"2000","journal-title":"Cancer"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199901000-00006"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201013378635"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(97)00041-6"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/15.5.419"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood.V86.7.2732.2732","article-title":"A murine cytokine fusion toxin specifically targeting the murine granulocyte\u2010macrophage colony\u2010stimulating factor (GM\u2010CSF) receptor on normal committed bone marrow progenitor cells and GM\u2010CSF\u2010dependent tumor cells","volume":"86","author":"Chan CH","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.V88.4.1445.bloodjournal8841445","article-title":"Reactivity of murine cytokine fusion toxin, diphtheria toxin390\u2010murine interleukin\u20103 (DT390\u2010mIL\u20103), with bone marrow progenitor cells","volume":"88","author":"Chan CH","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/10.9.1071"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21647"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:NEON.0000024219.47447.91"},{"key":"e_1_2_6_26_2","first-page":"2146","article-title":"Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer","volume":"54","author":"Myklebust AT","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10137"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2004.100.2.0320"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2004.101.6.1004"},{"key":"e_1_2_6_30_2","first-page":"2092","article-title":"The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography","volume":"53","author":"Sung C","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00046364"},{"key":"e_1_2_6_32_2","first-page":"5144","article-title":"Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for binding site barrier","volume":"52","author":"Juweid M","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_6_33_2","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single\u2010chain fv antibody molecules","volume":"61","author":"Adams GP","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.19.8999"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1227\/00006123-199604000-00024","article-title":"Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor","volume":"38","author":"Kroll RA","year":"1996","journal-title":"Neurosurgery"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1994.80.3.0520"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-005-9051-7"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)85069-X"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.3171\/foc.2005.19.4.4"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110647"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0173(94)00015-H"},{"key":"e_1_2_6_42_2","first-page":"671","article-title":"The role of microglia in brain injury","volume":"17","author":"Streit WJ","year":"1996","journal-title":"Neurotoxicology"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490410306"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19981001)54:1<7::AID-JNR2>3.0.CO;2-M"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00571506"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0464"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0559"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)32392-X"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb08213.x"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.111.2.783"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.10.2610"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.11.7566"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.11.13.9367352"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14.10.1335"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02700025"},{"key":"e_1_2_6_56_2","first-page":"230","article-title":"Vascular protection by chloroquine during brain tumor therapy with Tf\u2010CRM107","volume":"60","author":"Hagihara N","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199404000-00012"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/002215540104900211"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.22.10686"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.122.3.673"},{"key":"e_1_2_6_61_2","first-page":"688","article-title":"Endotoxin stimulates expression of the murine urokinase receptor gene in vivo","volume":"147","author":"Almus\u2010Jacobs F","year":"1995","journal-title":"Am J Pathol"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1177\/153303460600500307"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzh023"},{"key":"e_1_2_6_64_2","first-page":"1253","article-title":"Human glioma cells overexpressed receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin","volume":"1","author":"Debinksi W","year":"1995","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_65_2","first-page":"255","article-title":"An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link","volume":"9","author":"Debinski W","year":"1998","journal-title":"Crit Rev Oncog"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.22278","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.22278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:37:36Z","timestamp":1697243856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.22278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,30]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1,15]]}},"alternative-id":["10.1002\/ijc.22278"],"URL":"https:\/\/doi.org\/10.1002\/ijc.22278","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,30]]}}}